27 completed, 14 recruiting, 14 unknown, 4 active not recruiting. 18 Phase 2, 18 Phase 4, 17 Phase 3, 11 Not applicable, 2 Early Phase 1.
Follow Dapagliflozin 10mg Tab: new trials by email Literature Review of Dapagliflozin 10mg Tab trials Research Report on Dapagliflozin 10mg Tab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SGLT2i, Pioglitazone, and Ketone Production in T1D Dapagliflozin 10mg Tab, Pioglitazone 15 MG and 30mg, Placebo - Type1diabetes | Phase 3 | Recruiting | The University of Texas Health Science Center at San Antonio | 24 | 2026-07-01 | 2026-07-20 |
| Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome Dapagliflozin 10mg Tab, Placebo - Heart Failure, Acute Kidney Injury | Phase 2 | Recruiting | Yale University | 130 | 2026-03-05 | 2026-03-13 |
| The Effect of Dapagliflozin on Myocardial Strain in Patients With Acute Heart Failure Dapagliflozin 10mg Tab - Congestive Heart Failure Acute | Not applicable | Not yet recruiting | Qilu Hospital of Shandong University | 188 | 2026-02-01 | 2026-03-24 |
| A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP) Placebo, Dapagliflozin 10mg Tab - Gestational Hypertension, Hypertension in Pregnancy | Phase 4 | Recruiting | University of Michigan | 200 | 2025-03-02 | 2026-03-04 |
| Dapagliflozin in STEMI Dapagliflozin 10mg Tab, CMR - ST Elevation Myocardial Infarction, Myocardial Infarction | Phase 3 | Recruiting | Ottawa Heart Institute Research Corporation | 256 | 2025-01-20 | 2026-02-20 |
| Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART) Dapagliflozin 10mg Tab, Pitavastatin 4 Mg Oral Tablet, Rosuvastatin and Ezetimibe - HIV Infections, Weight Gain | Phase 3 | Active not recruiting | Kirby Institute | 300 | 2024-12-16 | 2026-07-22 |
| Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity Dapagliflozin 10mg Tab - Doxorubicin Induced Cardiomyopathy, Breast Cancer | Phase 2 | Recruiting | Tanta University | 46 | 2024-10-31 | 2026-04-17 |
| Cardiotoxicity in Breast Cancer Patients Dapagliflozin 10mg Tab - Breast Cancer | Phase 4 | Recruiting | Helwan University | 40 | 2024-09-10 | 2025-09-22 |
| Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury Dapagliflozin 10mg Tab - Acute Kidney Injury, Percutaneous Coronary Intervention | Phase 4 | Suspended | Albert Einstein Healthcare Network | 250 | 2024-09-01 | 2024-07-31 |
| IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency Iron Carboxymaltose, Dapagliflozin 10mg Tab, Placebo of Iron Carboxymaltose - Heart Failure, Systolic, Iron Deficiencies | Phase 3 | Not yet recruiting | Hospital de Clinicas de Porto Alegre | 99 | 2024-05-24 | 2024-06-03 |
| The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes Dapagliflozin 10mg Tab, Metformin 1000 mg (ttd), Placebo - Obesity, Dapagliflozin Adverse Reaction | Phase 4 | Active not recruiting | Oman Ministry of Health | 150 | 2024-04-22 | 2025-03-26 |
| SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF Dapagliflozin 10mg Tab, Placebo Tab - Chronic Coronary Syndrome, Atrial Fibrillation | Phase 3 | Recruiting | Region Örebro County | 800 | 2024-04-04 | 2025-04-08 |
| SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus Dapagliflozin 10mg Tab, Placebo 10mg Tab - Chronic Hepatitis B | Phase 4 | Recruiting | Chinese University of Hong Kong | 412 | 2024-03-26 | 2026-03-18 |
| Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients Dapagliflozin 10mg Tab, Pentoxifylline 400 MG - Chronic Kidney Diseases | Phase 3 | Unknown | Ain Shams University | 210 | 2024-03-01 | 2024-05-20 |
| Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients Dapagliflozin 10mg Tab, Placebo - Kidney Transplant; Complications, Vascular Diseases | Phase 4 | Recruiting | University of Colorado, Denver | 80 | 2024-02-01 | 2025-05-29 |
| MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin Dapagliflozin 10mg Tab, Placebo, Levothyroxine Replacement daily - Hepatic Steato-Fibrosis, Non-Alcoholic Fatty Liver Disease | Early Phase 1 | Active not recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 50 | 2024-01-15 | 2026-08-28 |
| Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients Dapagliflozin 10mg Tab, lifestyle interventions - Prediabetic State, Impaired Fasting Glucose | Phase 2 | Unknown | Yangjin | 120 | 2023-12-20 | 2023-07-25 |
| Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI Dapagliflozin 10mg Tab, Placebo - Myocardial Infarction | Not applicable | Recruiting | Mohammad Hussien Tantawy Soliman | 80 | 2023-12-20 | 2026-10-14 |
| PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care Dapagliflozin 10mg Tab, Placebo - Acute Kidney Injury | Phase 3 | Terminated | The George Institute | 51 | 2023-11-29 | 2026-03-30 |
| Effects of Dapagliflozin on Progression of Alport Syndrome Dapagliflozin 10mg Tab - Alport Syndrome | Unknown | Nanjing University School of Medicine | 222 | 2023-11-15 | 2024-09-05 |
Showing 20 of 64. Sign in to see all of them.
Renal Insufficiency, Chronic (9) · Diabetes Mellitus (7) · Diabetes Mellitus, Type 2 (6) · Heart Failure (6) · Acute Kidney Injury (4) · Breast Neoplasms (4) · Myocardial Infarction (4) · Non-alcoholic Fatty Liver Disease (3) · Albuminuria (2) · Angina, Unstable (2) · Atrial Fibrillation (2) · Critical Illness (2) · Fatty Liver (2) · Kidney Failure, Chronic (2) · Proteinuria (2)
Ain Shams University (3) · Cairo University (2) · Mansoura University (2) · Post Graduate Institute of Medical Education and Research, Chandigarh (2) · Tanta University (2) · University Medical Center Groningen (2) · Al-Balqa Applied University (1) · Albert Einstein Healthcare Network (1) · Albina Nowak, MD (1) · An-Najah National University (1) · Assiut University (1) · Centro Universitario de Ciencias de la Salud, Mexico (1) · Chinese University of Hong Kong (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Giaccari Andrea (1)
Egypt (13) · United States (11) · Italy (5) · India (4) · Mexico (4) · Brazil (3) · China (3) · Australia (2) · France (2) · Germany (2) · Hong Kong (2) · Netherlands (2) · Argentina (1) · Canada (1) · Czechia (1)
Abinet Aklilu, MD (1) · Adriana Marton, MD (1) · Amira B. Kassem, Lecturer (1) · Andrea Giaccari (1) · Ari Cedars (1) · Ashley Hesson, MD, PhD (1) · Ashu Rastogi, MD,DM (1) · Desmond Yap, MD (HK) (1) · Dominique Guerrot, MD, PhD (1) · Gail Matthews, MD (1) · German R Bautista Lopez, Cardiology (1)
PMID 31535829, PMID 10987628, PMID 11239408, PMID 17951284, PMID 19553646, PMID 20204386, PMID 21094444, PMID 22025886, PMID 22431131, PMID 22554256, PMID 23040488, PMID 23040716, PMID 23398530, PMID 23473396, PMID 23533715, PMID 23707905, PMID 23906374, PMID 25937196, PMID 26378978, PMID 26555703, PMID 26606676, PMID 26914659, PMID 28095900, PMID 28605608, PMID 28950419, PMID 29016744, PMID 29371333, PMID 29446769, PMID 29485006, PMID 29573529, PMID 29895557, PMID 30990260, PMID 31236801, PMID 31248555, PMID 31504439, PMID 32006266, PMID 32115470, PMID 32144994, PMID 32178931, PMID 32317958, PMID 32352644, PMID 32559474, PMID 32665641, PMID 32854852, PMID 32865377, PMID 32865597, PMID 33030307, PMID 33282811, PMID 33303068, PMID 33894597
2016 (1), K23DK142042 (1), R01DK024092 (1)